Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
Key facts
- Who runs it
- Actinium Pharmaceuticals
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- Mar 2023
- Ended
- Sept 2024
- Type of study
- Interventional
- Treatments tested
- Lintuzumab-Ac225
- Venetoclax
- Azacitidine
- Record updated
- 20 July 2023
- Why it stopped
- study postponed
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Histologically confirmed acute myeloid leukemia
- Refractory or relapsed AML which will include:; Refractory disease will be defined as at least 1 prior treatment with no remission; Relapsed disease will be defined as 5% or more blasts in bone marrow seen after remission; Patients with AML arising from myelodysplastic syndromes (including CMML) or myeloproliferative neoplasms (secondary AML, ts-AML) are also eligible
- White blood cell (WBC) count < 10 x 109/L; Use of hydroxyurea, prior to Cycle 1 and during Cycles 1 and 2, is permitted to lower the WBC count in the peripheral blood
- Age > 18 years
- Estimated creatinine clearance ≥ 50 mL/min calculated by the Cockroft-Gault formula
- AST and ALT ≤ 3.0 x ULN (unless considered to be due to leukemic organ involvement)
- Bilirubin ≤ 3.0 x ULN (unless considered to be due to leukemic organ involvement)
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
Who cannot take part
- Active CNS leukemia. Patients with symptoms of CNS involvement, particularly those with M4 or M5 subtypes, should undergo lumbar puncture prior to treatment on study to exclude CNS disease. Symptoms include cranial neuropathies, other neurologic deficits, and headache
- Have received prior radiation to maximally tolerated levels to any critical normal organ
- Participant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment
- Previous solid organ transplant (prior treatment with SCT is allowed but not if patient as GVHD or is still receiving immunosuppression/GVHD therapy)
- Clinically significant cardiac disease
- Active, uncontrolled serious infection
- Have other non-myeloid malignancy within 2 years of entry (with exceptions)
- Psychiatric disorder that would preclude study participation
- Have acute promyelocytic leukemia (APL)
About the trial
What the trial wants to find out
The study is a multicenter, open label Phase I/II trial.
Read full original descriptionShow less
1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in combination with venetoclax and azacitidine for patients with CD33 positive AML. (Phase I portion) 2. To assess the percentage of patients with CR, CRh, CRi, MLFS or Overall Response (CR + CRh + CRi + MLFS), up to 6 months after the start of treatment without receiving other AML therapies.. (Phase 2 portion)
The group in the trial
- Phase I and Phase IITreatment being tested
Lintuzumab-Ac225 will be administered on Day 8 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review). Venetoclax will be taken on Days 1-21 of each cycle for up to 12 cycles. Azacitidine will be administered on Days 1-7 of each cycle for up to 12 cycles. Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery.
Treatment: Lintuzumab-Ac225, Venetoclax, and Azacitidine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I/II Study of Venetoclax and Azacitidine and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML
- Record updated
- 20 July 2023